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Almost all patients who succumb to prostate cancer die of metastatic castration-resistant disease. Although docetaxel is the
standard treatment for this disease and is associated with modest prolongation of survival, there is an urgent need for novel
treatments for castration-resistant prostate cancer (CRPC). Great advances in our understanding of the biological and molecular
mechanisms of prostate cancer progression have resulted in many clinical trials of numerous targeted therapies. In this paper, we
review mechanisms of CRPC development, with particular focus on recent advances in the understanding of speciﬁc intracellular
signaling pathways participating in the proliferation of CRPC cells.
1.Introduction
Prostate cancer is the most common malignancy and the
second leading cause of cancer death in the United States
[1].TheAmericanCancerSocietyhasestimatedthat217,730
new cases will be diagnosed and 32,050 deaths will occur in
the United States in 2010. However, in Japan, the incidence
of prostate cancer was still lower than that of gastric and lung
cancer in 2005 but has been markedly increasing, and it is
predicted that the incidence will be second to lung cancer by
2020 [2]. In the early 1940s, Huggins demonstrated that the
growth and survival of prostate cancer are dependent upon
androgens [3]. Most patients with advanced prostate cancer
initially respond to androgen ablation therapy. However,
after an initial period of response to this therapy most of
these patients ﬁnally relapse and develop castration-resistant
prostate cancer (CRPC).
CRPC cells mostly continue to express androgen-regu-
lated genes, such as PSA, despite greatly reduced levels of
androgens. In particular, androgen receptor (AR) expression
is required for survival, and the AR signal axis is still
activatedinthisstate.Severalpossiblemechanismshavebeen
proposed, including: (a) the development of hypersensitive
response due to increased AR levels or de novo production of
endogenous androgens within the prostate; (b) promiscuous
activation of AR due to mutation in ligand binding domain
of AR; (c) altered transcriptional activity of AR due to
changes in expression of coactivators and/or corepressors;
(d) ligand-independent activation of AR through growth
signaling activation [4, 5]. Alternatively, other models sug-
gest that preexisting androgen-independent cancer cells in-
frequently occur within tumors and undergo clonal selection
during androgen deprivation therapy, resulting in CRPC [4].
2.PTEN-PI3KSignalingPathway
In 1997, the tumor suppressor gene PTEN was identiﬁed as
a gene that is mutated in multiple sporadic tumor types,
as well as in patients with predisposed cancer syndromes,
suchasCowdendisease[6–8].PTENnegativelyregulatesﬂux
through the phosphatidylinositol 3-kinase (PI3K) signaling
pathway [9], which plays a critical role in tumorigenesis in a
variety of malignancies. Therefore, the PTEN-PI3K signaling
pathway functions as a crucial regulator of cell survival fate.
Mouse models have shown that Pten heterozygotes develop
prostatic intraepithelial neoplasia (PIN), but these lesions do
not progress to invasive cancers [10]. On the other hand,
Pten heterozygosity cooperates with loss of other genes, such
as Nkx3.1 and Cdkn 1b (p27), in the development and2 Prostate Cancer
progression of prostate cancer [10]. Conditional knockout
mice, lacking both alleles of Pten, develop invasive prostate
cancer[10].Inhumanprostatecancer,lossofthePTEN gene
occurs in a substantial proportion of metastatic cancer and
in approximately 20% of locally advanced lesions [11]. By
contrast, only a minority of low-grade and low-stage tumors
harbor PTEN mutations [12]. Therefore, these data strongly
suggest that PTEN has a role as a tumor suppressor in pros-
tate cancer initiation and progression.
Use of a prostate-speciﬁc Pten deletion mouse model and
PTEN knockdown in cell lines revealed that loss of PTEN
promotes resistance to castration [13]. In spite of this evi-
dence, there are few studies that clearly explain the mech-
anism. Interestingly, Carver et al. recently showed that the
PI3K pathway and AR signaling regulate each other by recip-
rocalnegativefeedback,sothatinhibitionofoneactivatesthe
other [14]. They showed by mRNA transcriptome analyses
that PTEN loss strongly correlated with repression of AR
activity. Moreover, they revealed that inhibition of the PI3K
signaling pathway restores AR signaling in PTEN-deﬁcient
prostate cancer cells, suggesting that resistance to castration
can be reversed. One mechanism of AR signaling activation
by PI3K inhibition seems to be through relief of negative
feedback inhibition to HER kinases. Additionally, blockade
of AR pathways attenuates FKBP5 expression, which is
androgen dependent in prostate cancer cells, resulting in
increased AKT phosphorylation due to a reduction in
PHLPP protein levels since FKBP5 is a molecular chaperone
for the AKT phosphatase PHLPP. In their study they used
BEZ235,adualinhibitorofPI3KandmTORC1/2.Thus,BEZ
235 treatment in PTEN-deﬁcient prostate cancer cells does
not delineate which target is more potent for AR signal acti-
vation. This reciprocal negative feedback regulation between
androgenic and PTEN loss/PI3K-AKT signaling in pros-
tate cancer has also been reported by other groups [15].
However, according to previous experiments, activation of
the mTOR signaling pathway in LNCaP cells represses PSA
expression [16]. Conversely, treatment with rapamycin, an
mTOR inhibitor, increases PSA expression [16]. Since PI3K
regulates mTOR signaling activity, this evidence shows that
the PI3K/mTOR pathway negatively regulates AR signal
activity. Therefore, this bidirectional crosstalk between these
two critical survival pathways in prostate cancer provides a
reasonable rationale for simultaneously inhibiting both sig-
naling pathways [17, 18]. Additionally, evaluation of PTEN
status and appropriate AR pathway inhibition, together with
treatment with PI3K/mTOR inhibitor, could shed a ray of
hope in overcoming treatment of CRPC.
3. ProteinKinaseC andProstateCancer
ProteinkinaseC(PKC)isoformsareserine/threoninekinases
involved in the transduction of a signiﬁcant number of sig-
nals for the regulation of cell proliferation, diﬀerentiation,
tumorigenesis, apoptosis, and cytoskeleton remodeling [19,
20]. The PKC isozymes comprise a large family, which are
grouped by three subfamilies subdivided into conventional,
novel, and atypical isoforms according to their structure
and mechanisms of regulation. The conventional PKCs,
including PKCα,P K C βI, PKCβII, and PKCγ,a r ea c t i v a t e db y
calcium, phosphatidylserine (PS), and diacylglycerol (DAG).
The novel PKCs, including PKCδ,P K C ε,P K C η,a n dP K C θ,
require only PS and DAG for their activation. The atypical
PKCs, such as PKCλ/ι and PKCζ,r e q u i r eo n l yP St oa c t i v a t e
them [19–21].
The fact that PKC is a cellular receptor for the tumor-
promoting phorbol esters led us to consider and investigate
the role of individual PKC isozymes in carcinogenesis [22].
Metzger et al. recently reported that PKCβI phosphorylates
histoneH3atthreonine6(H3T6)andinhibitslysine-speciﬁc
demethylase 1 (LSD1), which is a component of corepressor
complexes of gene transcription, from demethylating H3K4
during AR-dependent gene activation [23]. They showed
that levels of PKCβI and phosphorylated H3T6 expression
positively correlate with high Gleason scores of prostate
cancer.Furthermore,inhibitionofPKCβIattenuatesprostate
cancer proliferation both in vitro and in vivo.
Hafeez et al. revealed that deletion of PKCε in TRAMP
mice inhibits prostate cancer development and metastasis
through downregulation of prostatic STAT3 activation and
STAT3-regulated gene expression [24]. A transgenic mouse
modelinwhichPKCε wasexpressedspeciﬁcallyinthemouse
prostate leads to the occurrence of prostate intraepithelial
neoplasia (PIN) through STAT3 activation, suggesting that
PKCε may be involved in prostate cancer development [25].
4.AtypicalPKC andCRPC
The atypical protein kinase C (aPKC) subfamily is composed
of two members, PKCλ/ι and PKCζ.P K C λ is the mouse
homolog of the human PKCι. The two isoforms are highly
related and show 72% amino acid similarity [26]. There is
growing evidence that aPKCs have been implicated in many
biologicalprocesses,includingcellsurvivalandproliferation,
cell polarity, and migration [5, 26]. Recently, several articles
showed participation of aPKCs in prostate cancer develop-
ment and progression. Par-4 binds both aPKCs and inhibits
the enzymatic activity [5, 26]. The Par-4 gene was originally
identiﬁed in prostate cells undergoing apoptosis following
androgen deprivation [5, 26]. Par-4 KO male mice showed
a high incidence of prostate hyperplasia and PIN [27]. Par-4
KOmalemiceweresensitivetotestosterone-inducedprostate
hyperplasia [27], and this hyperproliferation and develop-
ment of prostate neoplasia can be blocked by concomitant
attenuation of PKCζ in mice [28]. In human prostate cancer
specimens, a signiﬁcant and direct correlation between Par-4
and PTEN protein levels was observed. Most Par-4 positive
tumors were also positive for PTEN, whereas those tumors
with negative or low Par-4 expression also exhibited negative
or low expression of PTEN. PTEN inactivation has been
foundtobeassociatedwithaggressiveandhighGleasonscor-
ing cancers. Similarly, there was a correlation between Par-
4 loss and high Gleason scores. Interestingly, concomitant
loss of Par-4 in the context of PTEN heterozygosity resulted
in invasive prostate carcinoma in mice through activation
of Akt and a synergistic stimulation of NFκ-B [28]. These
observations suggest that Par-4 and PTEN have a strong co-
operative eﬀect on human prostate carcinogenesis.Prostate Cancer 3
All these ﬁndings suggest that aPKCs may have roles in
carcinogenesis and progression of prostate cancer.
We have established AILNCaP cells, which are derived
fromLNCaPcellsafterlong-termculturingunderandrogen-
deprived conditions. They can proliferate without andro-
gens, and thus this transition model mimics the clinical sta-
tus of patients who eventually become resistant to castration.
Using this model, we identiﬁed that activity of S6K signaling
pathway is regulated by androgen/AR signal, and activation
of the S6K signaling pathway is required for proliferation of
LNCaP cells [29]. Moreover, its constitutive activation is also
required for proliferation of AILNCaP cells under androgen-
deprived conditions. Through investigation of various sig-
naling pathways participating in activation of S6K pathway,
we clariﬁed that aPKCs activity regulates the upstream signal
of this pathway [29]. In LNCaP cells, androgen deprivation
reduced the amount of activated form of aPKCs. In contrast,
activated forms of aPKCs could be seen in AILNCaP cells
without androgen stimulation. Moreover, androgen stimu-
lation upregulated the degree of activated forms of aPKCs
in LNCaP cells. We also found that exogenously introduced
wild-type aPKCs were associated with S6K in prostate can-
cer cell lines and that this association correlated with an-
drogen stimulation. Inhibition of aPKCs using a speciﬁc
inhibitory peptide attenuates the activated form of S6K both
in LNCaP cells and AILNCaP cells. The same trend was
observed in the activated form of the downstream target S6,
and the expression of cyclin D1 was reduced in both cell
lines. Cell cycle and morphological analysis revealed that
inhibition of this pathway not only reduces cell proliferation
but also induces apoptosis. The same observation can be
seen in the AR-negative prostate cancer cell lines, PC3 and
DU145. Thus, the aPKC/S6K signaling pathway participates
in androgen-dependent proliferation of LNCaP cells, and
constitutive activation of this pathway is required for cell
proliferation and survival of androgen-independent prostate
cancer cells [29].
Investigation of upstream regulators of aPKCs/S6K path-
way revealed that Rac1, a member of Rho family small gua-
nosine triphosphatases (GTPases), is a critical regulator for
activation of the pathway [30]. Androgen stimulation in-
creased expression of Rac1-GTP, which is an activated form
of Rac1, and in contrast, androgen withdrawal attenuated
the amount of Rac1-GTP form in LNCaP cells. Moreover, in
this experiment, the amount of Rac1-GTP correlated with
theactivatedformsofaPKCsandS6K,andinhibitionofRac1
with pharmacological and genetic methods induced atten-
uation of the aPKCs/S6K signaling pathway. Furthermore,
treatment with Rac1 inhibitor signiﬁcantly inhibited the ef-
fect of androgen on cell cycle progression of LNCaP cells
[30]. Collectively, these results suggest that the Rac1-aPKC-
S6K signaling pathway is activated by androgen stimulation,
and activity of this pathway is required for cell cycle pro-
gression of LNCaP cells. Introduction of constitutively active
mutant Rac1 (Rac1V12) in LNCaP cells induced prolif-
eration under androgen-depleted conditions both in vitro
and in vivo [30]. Evaluation of Rac1 activation of syn-
geneic androgen-independent sublines of LNCaP cells, C4-
2, and AILNCaP cells, under androgen-depleted conditions,
revealed that Rac1-GTP is more abundant in these cell lines
compared with that expressed in LNCaP cells cultured in
the same conditions. Accordingly, both cell lines expressed
increased levels of the activated forms of aPKCs compared
with the parental cells. Attenuation of Rac1-GTP expression
by pharmacological and genetic methods in C4-2 and
AILNCaP cells reduced cell cycle progression and induced
apoptosis, indicating that activity of Rac1 is related to andro-
gen-independent progression and survival of LNCaP cells.
Moreover, PC3 and DU145 cells expressed more Rac1-GTP
compared with LNCaP cells, and attenuation of Rac1-GTP
expression by pharmacological and genetic methods reduced
cellcycleprogressionandinducedapoptosisinbothcelllines
[30]. In human prostate cancer tissues, Rac1/aPKCs/S6K sig-
naling is more highly activated in CRPC specimens in com-
parison to hormone-na¨ ıve cancers, as shown by immunohis-
tochemical analysis (Figure 1). Collectively, these results sug-
gest that the Rac1/aPKCs/S6K signaling pathway is required
for progression to androgen-independent states, and thus
this signaling pathway may be a potent therapeutic target of
CRPC [30]( Figure 2).
Interestingly, Ishiguro et al. have reported that PKCλ/ι
expression correlates with biochemical failure after radical
prostatectomy [31]. Additionally, they found that suppres-
sionofPKCλ/ιinDU145cellsattenuatestheirgrowthinvitro
and in vivo and showed evidence that PKCλ/ι mediates IL-6
gene transcription through NFκB and AP1 in prostate cancer
cells. They ﬁnally concluded that overexpression of PKCλ/ι
may participate in the progression to CRPC. Yao et al. have
demonstrated that expression of PKCζ in human prostate
cancer specimens highly correlated with existing prognostic
markers, such as Gleason score and clinical stage [32]. They
also reported that suppression of PKCζ by siRNA in PC3-M
cells reduced proliferation and invasive capacities.
These observations implicate that aPKCs have important
roleintheoccurrenceandprogressionofprostatecancerand
that this signaling pathway might be a target for CRPC.
5.ProstaglandinandCRPC
Inﬂammation has been considered to be a key player in pros-
tatecarcinogenesis,anddietaryconsumptionofnonsteroidal
anti-inﬂammatorydrugsmayreducetheriskofprostatecan-
cer [33, 34]. In prostate cancer patients, a strong association
between the levels of serum C-reactive protein (CRP) and
serum PSA has been reported [35]. Recently, elevated plasma
CRP level has been considered as a strong predictor of poor
prognosis in patients with metastatic CRPC [35].
Prostaglandins (PGs) have been considered to play a role
in the development and progression of many malignancies
[36, 37]. PGs promote carcinogenesis by multiple mecha-
nisms, such as enhancement of cell proliferation, inhibition
ofapoptosis,andpromotingangiogenesis.COX,anendoper-
oxidase synthase, is the rate-limiting enzyme that catalyzes
the conversion of arachidonic acid to PGs and related
eicosanoids [35, 37]. COX consists of two isoforms: COX-
1, which is constitutively expressed in variety of tissues and
cell types, and COX-2, which is induced its expression by4 Prostate Cancer
Androgen receptor Ki67 Phosphorylated-aPKC
Figure 1: Representative immunohistochemical staining of castration-resistant prostate cancer tissues by speciﬁc antibodies against
androgen receptor, Ki67, and phosphorylated atypical PKC.
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Figure 2: Intracellular signaling pathways including Rac1/atypical
PKC (aPKC)/S6K pathways and androgen signaling. An unknown
molecule (X) downstream of androgen/androgen receptor (AR)
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contribute to androgen-dependent cell proliferation. In castration-
resistant prostate cancers, AR activity is upregulated by speciﬁc
mutations for a promiscuous ligand-dependent manner or by other
mechanisms, resulting in constitutive activation of Rac1/aPKC/S6K
signaling through the same “X” or others.
a variety of stimuli [35, 37]. Genetic and clinical studies
suggested that increases in COX-2 expression is a key factor
in prostate carcinogenesis and COX2 inhibitors have been
tested in the treatment and prevention of prostate cancer
[35]. However, these approaches have met with limited suc-
cess and sometimes with severe cardiovascular toxicities
[38]. Prostaglandin E (PGE) and prostaglandin F (PGF)
are the major PGs stimulating the proliferation of prostate
cancer cells, and they act by binding to prostanoid receptors
and G-protein-coupled membrane receptors [35]. PGE acts
through four diﬀerent receptor subtypes, EP1 to EP4 [39].
Theintracellularsignalingdiﬀersamongthesereceptors;EP1
is coupled to calcium mobilization, EP3 inhibits adenylate
cyclase, and EP2 and EP4 stimulate adenylate cyclase in
various cell types [39]. Previous experimental studies have
implicated that increased EP2 and EP4 expression is impor-
tant in colorectal and prostate cancer progression [40, 41].
We have established and reported two novel prostate
cancer xenograft models, KUCaP-1 and KUCaP-2 [42, 43].
KUCaP-2 tumors are derived from locally recurrent CRPC
specimens, harborwild-type AR,andexpressPSA[43].They
regresssoonaftercastrationandrestoretheirabilitytoprolif-
erate after 1 to 2 months without AR mutations, mimicking
clinical transition to CRPC. Precise investigation of this
model revealed that EP4 expression signiﬁcantly increased
withthedevelopmentofcastrationresistance[43].Inhuman
prostate cancer specimens, the EP4 expression level was sig-
nificantly higher in CRPC rather than hormone-na¨ ıve pros-
tate cancer, which is compatible with the expression in
KUCaP-2 model. EP4 overexpression induced castration-
resistant proliferation in LNCaP cells both in vitro and in
vivo through activation of the EP4-cAMP-PKA-AR signaling
pathway. Treatment with speciﬁc EP4 antagonist, ONO-
AE3-208, in EP4-overexpressing LNCaP cells and KUCaP-
2 cells resulted in attenuation of their proliferation under
androgen-deprived conditions in vivo, suggesting that EP4
might be a novel molecular target of CRPC [43].
6. IntrinsicActivationof AndrogenReceptor
Recently, multiple kinds of AR alternative splicing variants
lacking various portions of the ligand-binding domain
(LBD) were identiﬁed in human prostate cancer specimens
[44,45].TheseARΔLBDvariantsareconsideredtobeconsti-
tutively active, so that AR signaling can be stimulated in the
complete absence of ligand binding. The clinical relevance
of these truncated ARΔLBD variants has also been reported.
The elevated expression of AR splice variants showed a sig-
niﬁcant association with more rapid disease recurrence after
radical prostatectomy, in comparison to patients with lower
expression levels of the variant [44]. Evaluation of specimens
derived from CRPC metastases revealed that variant mRNAs
ofanyformwereincreasedinthesespecimensincomparison
to normal prostate tissue samples [46]. Interestingly, a re-
cent report suggested that some AR variants promote cas-
tration-resistant growth by acting through full-length AR
and not independently [47]. Therefore, this growth is
inhibited by ligand binding domain-targeted antiandrogens,
such as MDV3100, or by speciﬁc siRNA for full-length AR.
Moreover, some AR variants displayed ligand-independent
biological activity, such as AR-V7, whereas AR-V1 had noProstate Cancer 5
eﬀect for castration-resistant tumor growth. Thus, the role
of AR variants in CRPC is complex, and furtherinvestigation
will be needed.
7.CrosstalkwithARSignalingandOther
TransductionPathways
Numerous papers have described crosstalk of AR signaling
withothertransductionpathways[4,48].Sincethereareover
500 putative protein kinase genes in the human genome, the
complexity and variety of signals that can be transduced are
enormous.
MutationsofSrckinasehavenotbeenreportedinhuman
prostate cancer, but Src kinase is overexpressed and activated
in metastatic or castration-resistant prostate cancer [49, 50].
The activation of Src kinase contributes to prostate carcino-
genesis through activation of various signaling pathways,
including RAS, PI3K-Akt, integrin-FAK, MAPK, and STAT3
signaling [51]. Several studies provide evidence that Src
kinase can interact with AR signaling pathways. Guo et al.
found that the Src kinase activity was elevated in all three
hormone-refractory prostate tumor xenografts [50]. Addi-
tionally, Src-induced tyrosine phosphorylation of AR, espe-
cially AR Y534, was critical for AR activation, and Src-
ARY534 phosphorylation was important for cell prolifera-
tion under androgen-depleted conditions in prostate cancer
cells. We reported that Src kinase activity was regulated
by androgen stimulation through AR in LNCaP cells [30].
Moreover, Cai et al. recently suggested that wild-type Src
kinase and AR mutually coactivate one another, and this
interaction contributed to prostate cancer progression in
vivo models [52]. Therefore, inhibition of Src kinase is now
considered as a promising therapeutic target of prostate can-
cer, and dasatinib, the dual Src and Bcr-Abl tyrosine kinase
inhibitor, is now under evaluation of for the treatment of
CRPC and metastatic prostate cancer [53].
Retinoblastoma (RB) is a tumor suppressor protein that
is frequently disrupted and has been considered as a critical
negative regulator of tumor development by preventing cell
cycle deregulation [54]. Recently, Sharma et al. presented
data revealing the contribution of RB in prostate cancer
progression to CRPC. They insisted that (1) RB loss of func-
tion was overrepresented in CRPC and metastatic prostate
cancer; (2) RB1 gene loss was frequently observed in CRPC;
(3) RB depletion was suﬃcient to induce castration-resistant
tumor growth through AR deregulation; (4) RB depletion
resulted in AR mRNA deregulation and protein accumu-
lation through stringent E2F1-mediated regulation; (5) per-
turbation of the RB/E2F/AR axis was frequently observed in
CRPC, resulting in AR upregulation [55].
In human prostate cancer, genomic alterations of ETS-
related genes, principally ERG, often occur as fusions
between an androgen receptor-regulated gene promoter of
TMPRSS2 and ETS transcription factors and are detected in
about 50% of tumors [56, 57]. This high frequency of ETS
genetic rearrangements led us to investigate contribution
of the aberrant ETS expression in prostate tumorigenesis.
These prostate cancer-speciﬁc gene rearrangements may
be explained by the fact that androgen treatment in AR-
positive prostate cancer cell lines induced proximity between
TMPRSS2 and ERG [58]. According to ERG transgenic
mousemodels,TMPRSS2-ERGaloneisinsuﬃcienttoinduce
prostatecarcinogenesis[59,60].However,whentheycrossed
this fusion transgene with Pten-deﬁcient mice, they obtained
oﬀspring that developed PIN and sometimes invasive adeno-
carcinoma [59, 60]. The majority of ERG-positive prostate
cancersampleshadreducedorabsentPTENexpression,sug-
gesting that ERG rearrangements and loss of PTEN were
concurrent genetic events [12, 59, 60]. Collectively, two
frequent critical events in human prostate cancer cooperate
to promote tumor development and progression in prostate
cancer. Recently, Yu et al. explored the genomic binding
s i t e so fE R Ga n dA R[ 61]. They found that there is an ex-
traordinary degree of overlap between these two crucial
transcription factors binding sites in prostate cancer. Pursing
this line of investigation, they found that ERG suppresses AR
function through a decrease in AR levels as well as inhibiting
AR transcriptional activity. Moreover, they suggested that
ERG regulates polycomb group protein EZH2-mediated epi-
genetic silencing. Thus, ERG may contribute to disruption of
androgen-mediated prostatic diﬀerentiation and induction
of EZH2-mediated cellular dediﬀerentiation. Additionally,
byinhibitingARsignaling,TMPRSS2-ERGmayexertaselec-
tive pressure for the development of CRPC. Kunderfranco et
al. revealed that ERG represses NKx3.1, a prostate-speciﬁc
homeobox protein involved in prostate development and
diﬀerentiation, through induction of EZH2 expression [62].
Although this supports work by Yu and colleagues, further
characterization of ERG and AR signaling is needed.
8. Conclusion
This paper highlights recent advances in understanding the
contribution of signal transduction pathways in the progres-
sion to CRPC. Although various new agents targeting AR
and testosterone synthetic pathways are under evaluation in
clinical trials, more eﬀective strategies will be necessary for
preventing the transition to lethal states of prostate cancer,
and this will require deeper understanding of underlying
mechanisms of CRPC.
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